Objective: To refine the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) as a measure of upper limb impairment following cervical SCI. Method: A cross-sectional study assessed a cohort of neurologically stable patients with tetraplegia using a preliminary version of the GRASSP. Regression analysis was performed to determine the association between subcomponents of the GRASSP (impairment) and measures of function. The GRASSP was modified based on results. Results: Eliminated static two-point discrimination, tone, and one muscle. Conclusion: The GRASSP Version I consists of Semmes Weinstein monofilaments, manual muscle testing, and qualitative and quantitative prehension testing.
tetraplegia will also be important to future pharmaceutical trials. Recently, due to the difficulty with assessment of the thoracic area, increased consideration is being given to enrolling subjects with cervical SCI in trials studying biological and pharmacological agents. 12, 13 It is hypothesized that neurological improvement in the cervical spinal cord is more likely to be reflected and detected as a change in upper limb function as compared to thoracic changes, which are difficult to assess. Furthermore, enrolling individuals with tetraplegia increases the number of potential subjects for studies, as almost two thirds of SCIs are cervical.
14 Increasing survival rates for cervical SCI have also driven interest in the development of a sensitive outcome measure for upper limb impairment. Researchers and experts have criticized prior trials 15 that used the International Standards for Neurological Classification of SCI, including the American Spinal Injury Association Impairment Scale (AIS), 16 as a primary outcome measure. The AIS was created and intended to be used as a clinical measure to classify injury severity, not as an outcome measure for efficacy in clinical trials. Nonetheless, the AIS has been utilized in many studies, and progress from human clinical trials has been hampered by the absence of a sensitive test for upper limb impairment, specifically the hand.
The first concentrated attempts by Sollerman and Ejeskar to measure hand function in the tetraplegic population met with limited success. 17 The Sollerman Hand Function Test was designed based on the conceptualization of normal hand function and did not adequately account for the impact of varying degrees and levels of cervical cord damage on hand impairment. Another outcome measure, the Danish Tetraplegia Hand Meaactivities such as locomotion, bowel and bladder care, recreation, and employment. Individuals with tetraplegia have identified upper limb function as one of the most significant factors contributing to quality of life.
1,2 Therefore, the more extensive upper limb recovery is following tetraplegia, the more functional an individual should be. In essence, upper limb function can equate to independence and global function for someone with tetraplegia.
Many investigators have studied ways to enhance upper limb movement (e.g., functional electrical stimulation and tendon transfer) 3, 4 and have subsequently assessed outcomes by measuring elements that were thought to be impacted by the interventions as opposed to changes in impairment or global function of the upper limb. Existing approaches to assessment have measured targeted parameters such as force, magnitude, and duration of grasp. [5] [6] [7] Values for grasp parameters, however, do not necessarily reflect subtle neurological change 8, 9 -change that may facilitate a more optimal movement pattern and improved hand function. Furthermore, subtle neurological change may be the only initial positive result observed with neuroprotective and neuroregenerative therapies in humans. 10, 11 To assess efficacy, one needs to determine the degree of change required to optimize function. Therefore, a comprehensive and sensitive measure of upper limb impairment/function is needed to document change post injury. Such a measure, which would depend on multiple factors such as the interplay between the sensory and motor domains of movement, is essential for future interventions intended to improve neurological recovery after spinal cord injury (SCI).
Assessment of upper limb recovery after sure, 18 was designed to measure the ability to complete functional tasks performed using a passive tenodesis grasp. Approaches to the use of tenodesis grasp are not universal, and the lack of specific protocols limits the utility of the test to certain parts of the world and a selective subgroup of individuals. The Jebsen- Taylor 
Development of the GRASSP
It became clear to the pharmaceutical industry and scientists in the field that approaches to measure and determine the efficacy of emerging therapies were lagging and an outcome measure was needed that was both sensitive and responsive to change-one that could be used to track natural recovery and the response of individuals receiving treatment. These issues served as the rationale for the development of the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP).
In May 2006, the North American Clinical Trials Network held a workshop in Chicago, Illinois, funded by the Christopher and Dana Reeve Foundation and Novartis International AG, Basel, Switzerland. The focus of the workshop was the discussion of the measurement of hand impairment and function in patients suffering from cervical SCI. Clinical specialists in hand measurement, rehabilitation practitioners, and SCI researchers with expertise in upper limb neurophysiology, engineering, and computer technology discussed the development of a comprehensive protocol to assess upper limb impairment and recovery post cervical SCI. At the conclusion of the meeting, a task force was formed to develop a new clinical protocol to assess upper limb (hand) impairment by modifying existing tools and introducing new measures intended to quantify changes in hand impairment starting immediately post injury. This led to the development of the alpha version of the GRASSP.
Theoretical Framework
The overall objective for the assembly of the GRASSP was the development of a clinical research measure that could (a) capture information on upper limb impairment for the cervical (C0-T1) SCI population, including data on integrated sensory and motor impairment; (b) discriminate according to the level of lesion; and (c) capture changes in hand impairment throughout the recovery phase. Sensorimotor function was defined as the major construct for the GRASSP, and a theoretical framework (Figure 1 ) was designed to guide development of the measure. The framework incorporated the concepts of motor control and motor learning theory, 24 which involve the interactions of the function (task), the individual, and the environment. 25 Task performance, which is dependent on integrated systems of sensation, motor, and cognition, was also incorporated. An integrated component was incorporated to assess how sensory and motor impairments contribute to an integrated function; this issue becomes increasingly important during the recovery process. When scoring is directed toward the quality and performance of movement (noting how the grasp is produced) more so than the ability alone (task performed or not), the results indicate which neurological elements are intact.
The initial GRASSP combined the preexisting Link Hand Function Test (LiHFT) 26 and the Tetraplegia Hand Measure (THM) 27 and incorporated three domains: strength and tone, sensibility (sensation), and prehension (integrated). The three domains provide the basis for the name of the measure, the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP). The inclusion of multiple domains ensures comprehensiveness of assessment. Each domain can be tested individually or in conjunction with another. Prior to 3 to 4 weeks post injury, it is recommended that a partial GRASSP be administered that consists of sensibility, strength and tone, and qualitative prehension only, because it is unlikely that the patient will tolerate enough sitting for the quantitative grasp portion of the test. However, if an individual is able to tolerate 45 minutes of sitting, a full GRASSP should be administered.
Phase I
Clinimetric development of the LiHFT and THM occurred during individual test development by Link 26 and Kalsi-Ryan et al, 27 respectively. Clinimetric development refers to the process of evaluating the clinical measurement properties of an assessment, such as feasibility, face, and content validity. The components of each test that met the criteria of the framework (see Figure  1 ) were selected and combined to create the GRASSP. Components adapted from the Li-HFT included five prehension tasks. In a similar fashion, the sensory module, part of the motor testing, and the scoring scale from the prehension tasks (combined with the LiHFT scoring scale) were adapted from the THM. All components included in the GRASSP are presented in Table 1 . The sensibility domain was assessed using Semmes Weinstein monofilaments (SWM) for light touch and static two-point discrimination (S2PD) for functional sensation. The strength/tone domain was assessed using manual muscle testing (MMT) for strength 28, 29 and the Modified Ashworth Scale for tone. 30 Both descriptive and performance-based prehension tests were incorporated to address the prehension domain. The descriptive prehension test evaluates whether the thumb and digits can assume three specific grasps or can perform any active movement at all. The performance-based prehension test is a modified version of the Sollerman Hand Function Test. 17 The Sollerman was modified by Link and Kalsi-Ryan et al during the development of the LiFHT and the THM. The prehension domain in the GRASSP retains the Sollerman concept of evaluating specific activity of daily living (ADL) tasks performed with specific grasps for evaluation. Details of the modifications made to the Sollerman Hand Function Test are available in the Appendix. Table 1 provides a summary of how the GRASSP is administered.
Phase II
Following initial development of the GRASSP, a cross-sectional study was used to determine which preliminary components should be included in the final GRASSP (GRASSP Version I). Seven centers collected data: Rehabilitation Institute of Chicago, Chicago, Illinois; Toronto Rehabilitation Institute, Toronto, Ontario; Vancouver Coastal Health, Vancouver, British Columbia; Thomas Jefferson University, Philadelphia, Pennsylvania; Balgrist University Hospital, Switzerland; Krakenhaus Hohe Worte, Germany; Traumacenter Murnau, Germany. Descriptive details for the study cohort (n = 72) are provided in Table 2 . Additional details of Phase II are outlined below.
Initial Evaluation and Refinement of the GRASSP
Regression analysis was conducted to determine which tests to include in the final GRASSP and to create a clinical index and/ or global score; however, sample size was not sufficient to perform the latter analysis. The GRASSP, Spinal Cord Independence Measure (SCIM), 31 Capabilities of Upper Extremity Questionnaire (CUE), 32 and International Standards for Neurological Classification of SCI (ISNCSCI) were administered to all study participants. General linear modeling was then used to establish the strength of the association between the components of the GRASSP (impairment) and function as defined by the SCIM (a measure of global function), the SCIM self-care subscore (a measure of upper limb function), and performance-based prehension tasks from the GRASSP (a measure of hand function). Individual subscores for each test within the GRASSP were calculated. SWM scores were separated into palmar and dorsal scores. GRASSP subscores were then compared to functional measures (SCIM, SCIM self-care subscore, and prehension). Functional measures were defined as the response variables and GRASSP subtests as the covariates. In addition, specific muscles within the MMT were also compared to functional measures including quantitative prehension tasks, again using general linear modeling. The strength of observed relationships between GRASSP impairment components and functional measures were used to exclude items and tests from the final GRASSP.
Preliminary components of the GRASSP were retained if there was a significant association with one of the three functional measures (SCIM, SCIM self-care subscore, and prehension). Strength of association was established by the p value. A p value ≤ .05 was considered significant and ≤ .10 approaching significance. General linear modeling results are summarized in Table  3 . There were no significant associations between tone (Ashworth), SWM dorsal sensation, and S2PD with the three response (functional) variables. These elements were subsequently eliminated from the GRASSP. The most significant associations were found for strength, SWM palmar sensation, and grasp function. Pearson correlation coefficients were conducted between S2PD and quantitative prehension tasks. Individual neurological levels (C6 and C7) showed weak, although significant, correlations with the three fine motor tasks of quantitative prehension (Task 3, 0.496; Task 5, 0.388; Task 6, 0.355; p < .001). The results of the linear modeling and poor correlations with prehension tasks justified removal of S2PD from the GRASSP.
In addition to applying general linear Table 3 . Modeling for GRASSP components
Step 1 i
Step 2 i
Step 3 Response modeling to determine which subtests to retain in the final GRASSP, a similar method was used to determine which individual muscles from the MMT should be retained based on the strength of association to function. Functional measures were again used as the response variables and individual muscles from MMT as the co-variates. A rating system was devised where individual muscles scored 1 for every significant association (p ≤ .05) to a response variable and a 0.5 if a relationship approached significance (p ≤ .10). Nine associations were evaluated for each individual muscle, and scores were summed for a maximal possible score of 9 ( Table 4) . Individual muscles were eliminated if their rating was less than 1. Based on the regression analysis, 10 muscles had a rating 1 or above. One muscle, the abductor policis brevis, was eliminated. Wrist extension only approached significance for the SCIM selfcare subscore; however, a decision was made to retain it in the final GRASSP due to its role as a key muscle in the ISNCSCI.
Summary and Future Steps
The GRASSP was conceived as an impairment measure for the upper limb that would be useful for assessing subtle neurological changes post cervical SCI during the acute, subacute, and postacute phases. Currently there is no validated and widely accepted measure for assessing the upper limb following cervical SCI. The preliminary work, presented in this article, successfully demonstrated a relationship among components of the GRASSP, measuring impairment, and function. To substantiate the efficacy and use of experimental agents for enhancing neurological recovery, future investigators will need to demonstrate both a change in impairment and a meaningful change in function through a responsiveness study. The GRASSP was developed to fill this gap and facilitate the performance of future clinical trials.
Based on the results of our analyses, the preliminary GRASSP was modified to maximize the link between impairment and function. Static two-point discrimination, magnitude of tone (Ashworth), and one muscle (abductor policis brevis) failed to demonstrate significant associations between impairment and function. These items were subsequently eliminated from the GRASSP. The current version (Version I) consists of SWM, MMT (10 muscles), and prehension testing. The development of the GRASSP represents one of the first steps to develop an upper limb impairment measure for SCI based on a large cohort of data.
The findings presented in this article are a small part of a larger, ongoing study designed to establish the reliability and validity of the GRASSP. A longitudinal study that will analyze the results of repeated measures of the GRASSP and functional measures of change on the same individuals over the course of a year will be undertaken. The results will provide data for responsiveness of the test, a recovery profile of the upper limb, and minimal clinically important differences of the upper limb for the tetraplegic population. 
Note:
Underlined values indicate muscles with significant or approaching significance association to function. SCIM = Spinal Cord Independence Measure. S1 = anterior deltoid; S2 = elbow extensor; S3 = elbow flexor; S4 = wrist extensor; S5 = extensor digitorum; S6 = flexor digitorum; S7 = flexor policis longus; S8 = abductor digiti minimi; S9 = first dorsal interossei; S10 = abductor policis brevis; S11= opponens policis.
